11 August 2022 – Global biotech leader CSL today announced that all business units will be united as one family under the CSL global brand.
“As a purpose-driven organization, CSL has delivered biotechnology excellence for over a century,” said Paul Perreault, Chief Executive Officer and Managing Director of CSL. “As we further advance our sustainable growth strategy, the timing is right to bring all the business units together under CSL. With one purpose, one strategy, one set of values and now one unified brand, our identity is clearly aligned where the whole is far greater than the sum of its parts.”
CSL Behring, which delivers therapies for rare and serious diseases, will maintain its current identity, as will CSL Plasma, the company’s plasma collection business. Seqirus, one of the world’s leading influenza vaccine providers, will become CSL Seqirus. Recently acquired Vifor Pharma will be known as CSL Vifor. CSL is in the process of formally changing the name for Seqirus and plans to change the names of the Vifor Pharma entities in due time.
CSL’s Values descriptions have been updated to reflect attributes from each business unit, but at their core they remain the same: Patient Focus, Innovation, Integrity, Collaboration and Superior Performance. A new creative campaign will help to launch the new global identity.
“Each business unit will continue to provide innovative products and services to patients and people in more than 100 countries around the globe as they do today,” said Perreault. “Our 30,000 employees, now sharing one DNA, will remain driven by our promise to put innovation into all we do – our passion, our products and our performance – for our patients and human health.”
